Alumis (ALMS) Accounts Payables (2023 - 2026)
Alumis' (ALMS) quarterly Accounts Payables came in at $12.8 million in Q2 2026, down 14.56% year-over-year from $15.0 million in Q2 2025, and up 26.66% quarter-over-quarter from $10.1 million in Q4 2025.
Analysis
Alumis (ALMS) Accounts Payables (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Accounts Payables for 4 consecutive years, with $12.8 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Accounts Payables fell 14.56% year-over-year to $12.8 million in Q2 2026; TTM through Jun 2026 was $12.8 million, a 14.56% decrease from a year earlier, with the FY2025 full-year figure at $10.1 million, up 5.01% from the prior year.
- Accounts Payables was $12.8 million for Q2 2026 at Alumis, up from $10.1 million in the prior quarter.
- Over five years, Accounts Payables peaked at $15.0 million in Q2 2025 and troughed at $1.1 million in Q4 2023.
- A 4-year average of $8.5 million and a median of $9.2 million in 2024 frame the typical range for Accounts Payables.
- Across the five-year window, Accounts Payables soared 760.82% in 2024 and decreased 29.33% in 2025, its largest moves.
- Over 4 years, Accounts Payables stood at $1.1 million in 2023, then soared by 760.82% to $9.6 million in 2024, then gained by 5.01% to $10.1 million in 2025, then grew by 26.66% to $12.8 million in 2026.
- The last three Accounts Payables figures came in at $12.8 million (Q2 2026), $10.1 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 2.87 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 674.00 Mn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 429.50 Mn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 1.16 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 167.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 1.52 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 403.90 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 25.08 Mn |
| 10 | Alumis | 966.94 Mn | 464.65 Mn | - | 12.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.80 Mn |
| Dec 31, 2025 | 10.11 Mn |
| Sep 30, 2025 | 4.55 Mn |
| Jun 30, 2025 | 14.98 Mn |
| Mar 31, 2025 | 7.47 Mn |
| Dec 31, 2024 | 9.62 Mn |
| Sep 30, 2024 | 6.44 Mn |
| Jun 30, 2024 | 9.19 Mn |
| Dec 31, 2023 | 1.12 Mn |